We could not find any results for:
Make sure your spelling is correct or try broadening your search.
L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - NGEN Canada NewsWire VANCOUVER, BC, le 21 mars 2024 VANCOUVER, BC, le 21 mars 2024...
Canadian Investment Regulatory Organization Trade Resumption - NGEN Canada NewsWire VANCOUVER, BC, March 21, 2024 VANCOUVER, BC, March 21, 2024 /CNW/ - Trading resumes in: Company: NervGen...
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING Canada NewsWire VANCOUVER, BC, March 21, 2024 /NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...
Suspension de la négociation par l'Organisme canadien de réglementation des investissements - NGEN Canada NewsWire VANCOUVER, BC, le 21 mars 2024 VANCOUVER, BC, le 21 mars 2024...
Canadian Investment Regulatory Organization Trading Halt - NGEN Canada NewsWire VANCOUVER, BC, March 21, 2024 VANCOUVER, BC, March 21, 2024 /CNW/ - The following issues have been halted by...
For anyone with a spinal cord injury (SCI), time is of the essence. The typical treatment scenario involves immobilization and surgery as quickly as possible. After that, managing To read the full...
Spinal cord injuries (SCI) can be devastating, and they can lead to a loss of mobility, sensation, and independence. There is no cure for SCI, and the treatments that are To read the full story on...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum...
The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset There is currently no...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions